Bondholders approve amendment to bond terms and conditions

14-01-2022   Regulatory press release

ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms and conditions of the Bonds (the "Proposal").

A sufficient number of bondholders participated in the written procedure in order to form a quorum, and a requisite majority of the bondholders voted in favour to approve the Proposal.

Each Bondholder is eligible to receive a consent fee in an amount equal to 0.75 per cent of the nominal amount of each Bond held by the relevant Bondholder on the Consent Fee Record Date (as defined in the Written Procedure) which will be 21 January 2022. Settlement of the consent fee is expected to occur on 28 January 2022.

The conditions for payment of the consent fee are specified in detail in the formal and detailed notice of the Written Procedure and are available on the Company's website, www.addvisegroup.com.
 

For further information, please contact:

Hanna Myhrman, General Counsel
+46 709 82 92 23
hanna.myhrman@addvisegroup.se


About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise acquires Seebreath AB

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Seebreath AB (“Seebreath”) regarding the acquisition of all the outstanding shares of Seebreath. The acquisition is in line with the letter of intent communicated via a press release dated February 28, 2022. Closing of the acquisition takes place today. Seebreath’s…

Interim report January 1 – March 31 2022

Regulatory

January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share…

ADDvise acquires Surplus Diabetics, Inc.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of Surplus Diabetics, Inc. (“Surplus Diabetics”) regarding the acquisition of all the outstanding shares of Surplus Diabetics in accordance with the letter of intent communicated via a press release dated January 17, 2022. Closing of the acquisition takes place today. Surplus…